晨化股份(300610) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was CNY 304,562,930.72, representing an increase of 81.86% compared to CNY 167,469,781.07 in the same period last year[7]. - Net profit attributable to shareholders was CNY 50,354,541.59, a significant increase of 154.75% from CNY 19,765,999.98 year-on-year[7]. - The net profit after deducting non-recurring gains and losses reached CNY 45,639,469.20, up 166.03% from CNY 17,155,912.79 in the previous year[7]. - The basic earnings per share (EPS) was CNY 0.33, reflecting a growth of 153.85% compared to CNY 0.13 in the same quarter last year[7]. - The total operating revenue for the first quarter of 2021 reached ¥304,562,930.72, compared to ¥167,469,781.07 in the previous period, representing an increase of approximately 81.8%[47]. - Net profit for the first quarter was ¥49,766,068.29, compared to ¥19,597,029.46 in the same period last year, reflecting an increase of approximately 153.5%[49]. - The company reported a total profit of ¥54,284,280.97 for the first quarter, compared to ¥22,066,634.75 in the previous year, an increase of approximately 145.0%[49]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,308,317,274.11, an increase of 12.18% from CNY 1,166,236,014.48 at the end of the previous year[7]. - The company's total assets as of March 31, 2021, were ¥1,134,925,791.67, up from ¥1,039,972,779.00 at the end of 2020, marking an increase of about 9.1%[44]. - The total liabilities of the company were CNY 281,020,536.77 as of March 31, 2021, compared to CNY 186,534,351.56 at the end of 2020, which is an increase of approximately 50.5%[40]. - Current liabilities increased to ¥175,440,358.20 from ¥107,881,363.74, representing a growth of approximately 62.5%[45]. Cash Flow - The net cash flow from operating activities was CNY 47,480,592.19, showing a 10.58% increase from CNY 42,938,338.62 in the same period last year[7]. - The cash flow from operating activities generated a net amount of ¥47,480,592.19, up from ¥42,938,338.62 in the previous period, reflecting a growth of approximately 12%[57]. - The company's cash and cash equivalents decreased to CNY 52,875,611.27 from CNY 180,416,364.93, a decline of approximately 70.7%[37]. - The ending balance of cash and cash equivalents was ¥41,668,452.61, down from ¥159,848,738.46 at the beginning of the period[61]. Research and Development - Research and development expenses increased by 89.19% to ¥10.30 million in Q1 2021, driven by an increase in the number and progress of R&D projects[16]. - The company has 26 ongoing R&D projects aimed at optimizing existing products and developing new ones[17]. - The company plans to invest in expanding its R&D capabilities to enhance product innovation and maintain competitive advantage[21]. - Research and development expenses for the first quarter were ¥10,301,078.18, up from ¥5,444,880.23, indicating an increase of approximately 89.5%[48]. Investments and Fundraising - The company reported a total fundraising amount of 21,822 million yuan, with 631.74 million yuan invested in the current quarter[27]. - Cumulative investment from fundraising reached 14,907.94 million yuan, with 18.36% of the funds having been repurposed[27]. - The project for producing 15,000 tons of alkyl glycosides has achieved 90.46% of its investment target, totaling 5,337.4 million yuan[27]. - The total investment for the R&D building project has increased from 40.06 million to 109.18 million, with 40.06 million sourced from previous fundraising and 69.12 million from company self-funding[28]. Risks and Challenges - Risks include intensified industry competition and potential quality control issues, which could adversely affect business operations and reputation[20]. - The company faces risks related to the transportation of hazardous chemicals, which could impact raw material supply and daily operations[22]. - The retirement of a core technical staff member may affect the company's technological capabilities[23]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,317[11]. - The company has not reported any overdue commitments from major stakeholders during the reporting period[25]. - There are no non-operational fund occupations by controlling shareholders or related parties reported during the period[31]. Corporate Governance - The company has successfully renewed its high-tech enterprise certification, allowing it to continue enjoying a 15% corporate income tax rate until 2022[23]. - The company has not reported any violations regarding external guarantees during the reporting period[30]. - The company has conducted investor relations activities, discussing operational conditions and market management with institutional investors[32].